Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
All content for HealthTech Israel Podcast is the property of Chen Sirkis and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
Prof. Varda Shalev, Co-Founder & Chief Medical Officer - Alike Health
HealthTech Israel Podcast
50 minutes
4 years ago
Prof. Varda Shalev, Co-Founder & Chief Medical Officer - Alike Health
Prof. Varda Shalev, Co-Founder & Chief Medical Officer at Alike.HealthProf. Varda Shalev is a practicing Primary Care Physician, a medical researcher, associate professor of medicine at the Tel Aviv University School of Public Health, founding director of the Macabbi Institute for Research and Innovation KSM and recently the co-founder and Chief Medical Officer of Alike Health - a healthcare startup developing an AI-based system designed to help patients manage their medical data, m...
HealthTech Israel Podcast
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
